Ravi Kishore Narra, MD, MS

Publications

• Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study.

  (Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, Hunter C, Kota V, Othman TA, Jonas B, Desai S, de Camargo Correia GS, Patel A, DuVall AS, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M.) Am J Hematol. 2024 Dec;99(12):2388-2391 PMID: 39253997 SCOPUS ID: 2-s2.0-85203436363 09/10/2024

• Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.

  (Muthiah C, Narra R, Atallah E, Juan W, Szabo A, Guru Murthy GS.) Leuk Res. 2024 May;140:107496 PMID: 38547577 SCOPUS ID: 2-s2.0-85188991221 03/29/2024

• Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.

  (Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B.) Br J Haematol. 2024 Mar;204(3):887-891 PMID: 38054558 SCOPUS ID: 2-s2.0-85178904872 12/06/2023

• The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.

  (Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C.) Haematologica. 2024 Mar 01;109(3):906-914 PMID: 37646658 PMCID: PMC10905074 SCOPUS ID: 2-s2.0-85178101970 08/30/2023

• Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.

  (Shayeb AM, McManus HD, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan CL, Barata P, Bilen MA, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan MD, McGregor B, Choueiri TK, McKay RR.) Clin Genitourin Cancer. 2023 Feb;21(1):55-62 PMID: 36411184 SCOPUS ID: 2-s2.0-85142487844 11/22/2022

• Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.

  (Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N.) Hematol Oncol. 2022 Feb;40(1):48-56 PMID: 34763367 SCOPUS ID: 2-s2.0-85119403860 11/12/2021

• Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.

  (Wong M, Narra R, Selim M, Zimmerman MA, Kim J, Padmanabhan A, Hong JC.) J Surg Res. 2020 Nov;255:99-105 PMID: 32543385 SCOPUS ID: 2-s2.0-85086399641 06/17/2020

• Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them.

  (Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN.) Biol Blood Marrow Transplant. 2020 Jul;26(7):1288-1297 PMID: 32135202 SCOPUS ID: 2-s2.0-85083636589 03/07/2020

• Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.

  (Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN.) Cancer. 2020 Jun 15;126(12):2791-2801 PMID: 32154922 SCOPUS ID: 2-s2.0-85081273628 03/11/2020

• From Theory to Practice: Implementation of Strategies to Reduce Acute Care Visits in Patients With Cancer.

  (Daly B, Michaelis LC, Sprandio JD, Kapke JT, Narra RK, Malosh E, Zervoudakis A, Holland J, Zablocki M.) Am Soc Clin Oncol Educ Book. 2020 May;40:85-94 PMID: 32421450 05/19/2020

• Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.

  (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN.) Biol Blood Marrow Transplant. 2020 May;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.0-85080146585 01/27/2020

• Allogenic transplant for non-hodgkin lymphoma

  (Narra RK, Shah NN.) Hematopoietic Cell Transplantation for Malignant Conditions. 1 January 2019:209-229 SCOPUS ID: 2-s2.0-85082261875 01/01/2019